trial

Study of m-RESIST, an m-Health Program for Treatment-resistant Schizophrenia

NCTId NCT03064776
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
— · Completed
Enrollment 43 (actual)
Sponsored by Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Primary completion 2017-07-01
Synthesized from structured facts only — each point cited above.

Design & status

Phase
—
Status
Completed
Enrollment
43 (actual)
Study type
Interventional
Allocation
Non Randomized
Model
Parallel
Masking
None
Start
2017-03-01
Primary completion
2017-07-01
Eligibility
ALL · 18 Years · 45 Years

Interventions & indications

Drugs
m-RESIST Patientsm-RESIST Caregivers

Sponsors

Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant PauLead Sponsor
Sheba Medical CenterCollaborator
Semmelweis UniversityCollaborator
iMindsCollaborator
Agència de Qualitat i Avaluació SanitàriesCollaborator

Investigators

1
Corripio Iluminada, MD, PhDPrincipal Investigator

Sites

3 total
Budapest, HungaryTel Aviv, IsraelBarcelona, Spain

Facts & assertions

4 sourced
Enrollment
43
Phase
NA
Primary Completion Date
2017-07-01
Status
COMPLETED
relationships
The graph out of here
drug
m-RESIST Patients
drug
m-RESIST Caregivers
drug
lead_sponsor
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
company
collaborator
Sheba Medical Center
company
Semmelweis University
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
Corripio Iluminada, MD, PhD
person